

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



EVEREST MEDICINES

云 頂 新 耀

Everest Medicines Limited

雲頂新耀有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 1952)

**VOLUNTARY ANNOUNCEMENT
VOLUNTARY LOCK-UP UNDERTAKING BY CONTROLLING
SHAREHOLDER AND CERTAIN SENIOR MANAGEMENT**

This announcement is made by Everest Medicines Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The board of directors (the “**Director(s)**”) of the Company announces that the Company has been informed by CBC Group, the controlling shareholder of the Company, Mr. Yongqing Luo, an executive Director and the Chief Executive Officer of the Company, and Mr. Ian Ying Woo, an executive Director and the Chief Financial Officer of the Company, that each of them has voluntarily undertaken not to dispose of any shares of the Company directly or indirectly owned by it/him for a period of at least 6 months, which are based on strong confidence in the Company’s future prospect and long-term development.

By order of the Board
Everest Medicines Limited
Wei Fu
Chairman and Executive Director

Hong Kong, 18 March 2024

As at the date of this announcement, the Board comprises Mr. Wei Fu as Chairman and Executive Director, Mr. Yongqing Luo and Mr. Ian Ying Woo as Executive Directors, Mr. William Ki Chul Cho and Mr. Honggang Feng as Non-executive Directors, and Ms. Hoi Yam Chui, Mr. Yifan Li and Mr. Shidong Jiang as Independent Non-executive Directors.